Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research
- PMID: 37646041
- PMCID: PMC10461559
- DOI: 10.3389/fimmu.2023.1202150
Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research
Abstract
Background: Interferon-gamma (IFN-γ), commonly referred to as type II interferon, is a crucial cytokine that coordinates the tumor immune process and has received considerable attention in tumor immunotherapy research. Previous studies have discussed the role and mechanisms associated with IFN-γ in specific tumors or diseases, but the relevant role of IFN-γ in pan-cancer remains uncertain.
Methods: TCGA and GTEx RNA expression data and clinical data were downloaded. Additionally, we analyzed the role of IFN-γ on tumors by using a bioinformatic approach, which included the analysis of the correlation between IFN-γ in different tumors and expression, prognosis, functional status, TMB, MSI, immune cell infiltration, and TIDE. We also developed a PPI network for topological analysis of the network, identifying hub genes as those having a degree greater than IFN-γ levels.
Result: IFN-γ was differentially expressed and predicted different survival statuses in a majority of tumor types in TCGA. Additionally, IFN-γ expression was strongly linked to factors like infiltration of T cells, immune checkpoints, immune-activating genes, immunosuppressive genes, chemokines, and chemokine receptors, as well as tumor purity, functional statuses, and prognostic value. Also, prognosis, CNV, and treatment response were all substantially correlated with IFN-γ-related gene expression. Particularly, the IFN-γ-related gene STAT1 exhibited the greatest percentage of SNVs and the largest percentage of SNPs in UCEC. Elevated expression levels of IFN-γ-related genes were found in a wide variety of tumor types, and this was shown to be positively linked to drug sensitivity for 20 different types of drugs.
Conclusion: IFN-γ is a good indicator of response to tumor immunotherapy and is likely to limit tumor progression, offering a novel approach for immunotherapy's future development.
Keywords: IFN-γ; immunotherapy; pan-cancer; single-cell transcriptome sequencing; tumor microenvironment.
Copyright © 2023 Wei, Ruan, Zhang, Qin, Zhang, Qin and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures













Similar articles
-
Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.Front Immunol. 2022 Sep 29;13:998266. doi: 10.3389/fimmu.2022.998266. eCollection 2022. Front Immunol. 2022. PMID: 36248785 Free PMC article.
-
A myeloid IFN gamma response gene signature correlates with cancer prognosis.Clin Transl Med. 2025 Apr;15(4):e70139. doi: 10.1002/ctm2.70139. Clin Transl Med. 2025. PMID: 40165405 Free PMC article.
-
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Front Immunol. 2021 Aug 31;12:721030. doi: 10.3389/fimmu.2021.721030. eCollection 2021. Front Immunol. 2021. PMID: 34531868 Free PMC article.
-
Portraying the dark side of endogenous IFN-λ for promoting cancer progression and immunoevasion in pan-cancer.J Transl Med. 2023 Sep 11;21(1):615. doi: 10.1186/s12967-023-04453-4. J Transl Med. 2023. PMID: 37697300 Free PMC article. Review.
-
A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).Front Genet. 2022 Jul 22;13:927046. doi: 10.3389/fgene.2022.927046. eCollection 2022. Front Genet. 2022. PMID: 35937984 Free PMC article. Review.
Cited by
-
Identification and Validation of a Prognostic Model Based on Tumour Necrosis Factor-Related mRNAs for Kidney Renal Clear Cell Carcinoma.J Cell Mol Med. 2025 Jul;29(14):e70657. doi: 10.1111/jcmm.70657. J Cell Mol Med. 2025. PMID: 40673609 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous